Sectors

SK Biopharmaceuticals will divest a 12% stake in Arvelle, which is looking to commercialise an epilepsy drug treatment, through the acquisition.

Bristol Myers Squibb participated in a series B round for the oncology drug developer that pushed its overall funding to $168m.

The oncolytic virus therapy-based cancer drug developer raised $77m in a GV-backed series A round as it prepares to file an IND application next year.

Amazon has agreed to acquire Walt Disney and Bertelsmann-backed podcast creator and publisher Wondery for about $300m.

The heart disease therapy developer completed a $12.7m round that included Alfresa, Dai-ichi Life, Sony Innovation Fund and Japan Lifeline.

Ionis Pharmaceuticals and Johnson & Johnson Innovation – JJDC were among the investors in a round that will fund development of Aro's centyrin-RNA conjugate medicines.

Kirin has become the first known corporate investor to take a small stake in the beer brand, in a deal valuing it a bit below $300m.

The corporate will get a majority stake in end-to-end construction services provider Katerra, helping it avoid bankruptcy protection.

The Alphabet, GSK, WuXi AppTec, Johnson & Johnson, Roche and Illumina-backed genetic testing service has now raised over $870m altogether.

Hanwha Systems has agreed to provide $30m in funding for the satellite technology provider, whose existing investors include Liberty Global and Intelsat.

Andre Maciel set up Volpe Capital in 2019 with SoftBank’s backing and it plans to invest in up to 20 early stage companies.